Patents by Inventor Janos Kodra

Janos Kodra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl carbonyl derivatives as therapeutic agents
    Publication number: 20080119455
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Dharma Polisetti, Janos Kodra, Jesper Lau, Paw Bloch, Maria Valcarce-Lopez, Niels Blume, Mustafa Guzel, Kalpathy Santhosh, Adnan Mjalli, Robert Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Aryl carbonyl derivatives as therapeutic agents
    Publication number: 20080119454
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Dharma Polisetti, Janos Kodra, Jesper Lau, Paw Bloch, Maria Valcarce-Lopez, Niels Blume, Mustafa Guzel, Kalpathy Santhosh, Adnan Mjalli, Robert Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Insulin Derivatives
    Publication number: 20080076705
    Abstract: The present invention relates to insulin derivatives having a side chain attached either to the -amino group of the N-terminal amino acid residue of the B chain or to the amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.
    Type: Application
    Filed: February 1, 2006
    Publication date: March 27, 2008
    Inventors: Janos Kodra, Patrick Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Peter Madsen, Tina Tagmose
  • N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes
    Publication number: 20070027140
    Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherin A and B are further defined in the application.
    Type: Application
    Filed: May 24, 2006
    Publication date: February 1, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Per Vedso, Janos Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan Mjalli, Robert Andrews, Dharma Pollisetti, Daniel Christen
  • Novel Glucagon Antagonists/Inverse Agonists
    Publication number: 20070015757
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: June 18, 2006
    Publication date: January 18, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Peter Madsen, Jesper Lau, Janos Kodra, Inge Christensen
  • Aryl carbonyl derivatives as therapeutic agents
    Publication number: 20060183783
    Abstract: This invention relates to aryl carbonyl derivativeswhich are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: March 1, 2006
    Publication date: August 17, 2006
    Inventors: Dharma Polisetti, Janos Kodra, Jesper Lau, Paw Bloch, Maria Lopez, Niels Blume, Mustafa Guzel, Kalpathy Santhosh, Adnan Mjalli, Robert Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
    Publication number: 20060182714
    Abstract: The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 17, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Carsten Behrens, Florencio Dorwald, Mikael Kofod-Hansen, Jesper Lau, Janos Kodra, Thomas Hansen, Paw Bloch
  • GLP-2 derivatives
    Publication number: 20060105948
    Abstract: The present invention relates to novel derivatives of human glucagon-like peptide-2 (GLP-2) peptides, which have a protracted profile of action, as well as pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: September 22, 2005
    Publication date: May 18, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Janos Kodra, Nils Johansen, Lars Thim, Bernd Peschke
  • Novel glucagon antagonists/inverse agonists
    Publication number: 20050256175
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: February 22, 2005
    Publication date: November 17, 2005
    Inventors: Jesper Lau, Inger Christensen, Peter Madsen, Paw Bloch, Carsten Behrens, Janos Kodra, Poul Nielsen
  • Glucagon antagonists/inverse agonists
    Publication number: 20050203108
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 15, 2005
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Christensen, Behrend Lundt, Ulla Sidelmann, Henning Thogersen, Anthony Ling, Michael Plewe, Larry Truesdale, Anker Jogensen, Janos Kodra, Shenghua Shi